Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Convergent identification and interrogation of tumor-intrinsic factors for immune escape in vivo

ABSTRACT: Evading immune destruction is a hallmark of cancer and a key feature for the resistance to cancer immunotherapy. Genetic alterations can directly influence the nature of cancer cells in the native tumor microenvironment to mediate immune escape. Our genome-scale in vivo CRISPR screens robustly identified multiple regulators of tumor-intrinsic factors that alter the ability of cells to grow as tumors across different levels of immunocompetence. As a convergent hit from these screens, Prkar1a mutant cells are able to robustly outgrow as tumors in fully immunocompetent hosts. Functional interrogation showed that Prkar1a loss greatly altered the transcriptome and proteome involved in inflammatory and immune responses as well as extracellular protein production. Single cell transcriptomic profiling and flow cytometry analysis mapped the tumor microenvironment of Prkar1a mutant tumors, and revealed the transcriptomic alterations in host myeloid cells. Taken together, tumor-intrinsic mutations in Prkar1a led to drastic alterations in the genetic program of cancer cells, thereby remodeling the tumor microenvironment.

ORGANISM(S): Mus musculus

PROVIDER: GSE123824 | GEO | 2019/12/13

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Prkar1a_SILAC_Proteomics

Project description:Evading immune destruction is a hallmark of cancer and a key feature for the resistance to cancer immunotherapy. Genetic alterations can directly influence the nature of cancer cells in the native tumor microenvironment to mediate immune escape. Our genome-scale in vivo CRISPR screens robustly identified multiple regulators of tumor-intrinsic factors that alter the ability of cells to grow as tumors across different levels of immunocompetence. As a convergent hit from these screens, Prkar1a mutant cells are able to robustly outgrow as tumors in fully immunocompetent hosts. Functional interrogation showed that Prkar1a loss greatly altered the transcriptome and proteome involved in inflammatory and immune responses as well as extracellular protein production. Single cell transcriptomic profiling and flow cytometry analysis mapped the tumor microenvironment of Prkar1a mutant tumors, and revealed the transcriptomic alterations in host myeloid cells. Taken together, tumor-intrinsic mutations in Prkar1a led to drastic alterations in the genetic program of cancer cells, thereby remodeling the tumor microenvironment.

2020-05-26 | PXD011837 | Pride

In vivo CRISPR screens reveals SerpinB9 and Adam2 as regulators of immune therapy in lung cancer

Project description:We established a direct in vivo CRISPR/Cas9 gene editing methodology that allowed us to assess the immune-modulatory capabilities of 573 putative cancer genes associated with altered activity in mouse model of lung cancer. Using mouse models of of KrasG12D- and BrafV600E-driven lung cancer, we identified Serpinb9 as our top suppressive and Adam2 as our top enhancing gene. RNA seq analysis from tumors overexpressing Adam2 revealed that Adam2’s oncogenic function is dependent on modulating the tumor immune microenvironment by restraining productive type I and type II interferon responses as well as cytokine signaling, reducing presentation of tumor associated antigen, and modulating surface expression of several immunoregulatory receptors within Kras-driven lung tumors. Adam2 overexpression also led to reduction in expression of immune checkpoint inhibitors such as PD-L1, Lag3, Tigit, and Tim3.This less exhausted tumor microenvironment further induced enhanced cytotoxic efficacy against Adam2 overexpressing lung tumors, in vitro and in vivo. Together, our study highlights the power of integrating cancer genomic with in vivo CRISPR/Cas9 screens to uncover how cancer-associated genetic alterations control responses to immunotherapies.

2023-01-31 | GSE200628 | GEO

GNPS - Integrative proteogenomic characterization of colorectal cancer cell lines and primary tumors

Project description:Solid tumors are complex organs comprising neoplastic cells and stroma, yet cancer cell lines remain widely used to study tumor biology, biomarkers and experimental therapy. Here, we performed a fully integrative analysis of global proteomic data comparing human colorectal cancer (CRC) cell lines to primary tumors and normal tissues. We found a significant, systematic difference between cell line and tumor proteomes, with a major contribution from tumor stroma proteomes. Nevertheless, cell lines overall mirrored the proteomic differences observed between tumors and normal tissues, in particular for genetic information processing and metabolic pathways, indicating that cell lines provide a system for the study of the intrinsic molecular programs in cancer cells. Intersection of cell line data with tumor data provided insights into tumor cell specific proteome alterations driven by genomic alterations. Our integration of cell line proteogenomic data with drug sensitivity data highlights the potential of proteomic data in predicting therapeutic response. We identified representative cell lines for the proteomic subtypes of primary tumors, and linked these to drug sensitivity data to identify subtype-specific drug candidates.

2016-12-01 | MSV000080374 | GNPS

High sensitivity receptor screen and global phosphoproteomics identifies podoplanin as a regulator of cancer associated fibroblast physiology

Project description:Cancer-associated fibroblasts (CAFs) are increasingly recognized as key regulatory cells in the tumor microenvironment, with the ability to engage in crosstalk both with tumor and immune cells. Still, the molecular determinants that orchestrate the interactions between CAFs and infiltrating immune cells remain poorly understood. To elucidate the surface interactome that underlines cell communication, we build an extensive library of single transmembrane (STM) receptors coupled to high avidity cell-based screens, and identify the neutrophil and Treg surface protein CD177 as a novel functional modulator of the mechanoreceptor podoplanin (PDPN). Functionally, CD177 exerts a profound effect on the phosphoproteome of CAFs that results in modulation of actomyosin contractility and energy homeostasis. In human colorectal tumors, CD177+ cells can interact closely with PDPN+ CAFs, indicating that this interaction may have effects on the local tumor environment. Starting from a powerful technology for target discovery, our study defines a molecular bridge between CAFs and immune cells in the tumor microenvironment and reveals PDPN as a central modulator of fibroblast mechanophysiology.

2019-03-18 | MSV000083594 | MassIVE

Expression changes in Melanomas pre MAPKi treatment vs. on MAPKi treatment (RNA-seq_Patient.batch3)

Project description:Treatment of advanced V600BRAF mutant melanoma using a BRAF inhibitor (BRAFi) or its combination with a MEKi typically elicits partial responses. We compared the transcriptomes of patient-derived tumors regressing on MAPKi therapy against MAPKi-induced temporal transcriptomic states in human melanoma cell lines or murine melanoma in immune-competent mice. Despite heterogeneous dynamics of clinical tumor regression, residual tumors displayed highly recurrent transcriptomic alterations and enriched processes, which were also observed in MAPKi-selected cell lines (implying tumor cell-intrinsic reprogramming) or in bulk mouse tumors (and the CD45-negative or -positive fractions,, implying tumor cell-intrinsic or stromal/immune alterations, respectively). Tumor cell-intrinsic reprogramming attenuated MAPK-dependency, while enhancing mesenchymal, angiogenic and IFN-inflammatory features and growth/survival dependence on multi-RTKs and PD-L2. In the immune compartment, PD-L2 upregulation in CD11c+ immunocytes drove the loss of T-cell inflammation and promoted BRAFi resistance. Thus, residual melanoma early on MAPKi therapy already displays potentially exploitable adaptive transcriptomic, epigenomic, immune-regulomic alterations.

2017-09-08 | GSE103658 | GEO

Expression changes in melanoma cell lines pre MAPKi treatment vs. post-MAPKi resistance (RNA-seq_CellLine.batch2)

2017-09-08 | GSE103630 | GEO

Expression changes in Melanomas pre MAPKi treatment vs. on MAPKi treatment (Affymetrix)

2017-09-05 | GSE75311 | GEO

Expression changes in Melanomas pre MAPKi treatment vs. on MAPKi treatment (RNA-seq)

2017-09-05 | GSE75299 | GEO

Expression changes in Melanomas pre MAPKi treatment vs. on MAPKi treatment [Y1.7.FPKM.batch1.2]

2017-09-13 | GSE103725 | GEO

Expression changes in YUMM1.7 melanoma with/without PD-L2 overexpression under BRAFi treatment in NSG mice [Y1.7.FPKM.batch4]

2017-09-12 | GSE103713 | GEO